ATE434431T1 - Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung - Google Patents

Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung

Info

Publication number
ATE434431T1
ATE434431T1 AT04798989T AT04798989T ATE434431T1 AT E434431 T1 ATE434431 T1 AT E434431T1 AT 04798989 T AT04798989 T AT 04798989T AT 04798989 T AT04798989 T AT 04798989T AT E434431 T1 ATE434431 T1 AT E434431T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
short chain
formulations containing
containing short
sphingolipids
Prior art date
Application number
AT04798989T
Other languages
English (en)
Inventor
Robert Veldman
Blitterswijk Wim Van
Marcel Verheij
Gerben Koning
Original Assignee
Het Nl Kanker I The Netherland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0326642A external-priority patent/GB0326642D0/en
Priority claimed from GB0326759A external-priority patent/GB0326759D0/en
Application filed by Het Nl Kanker I The Netherland filed Critical Het Nl Kanker I The Netherland
Application granted granted Critical
Publication of ATE434431T1 publication Critical patent/ATE434431T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04798989T 2003-11-14 2004-11-11 Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung ATE434431T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326642A GB0326642D0 (en) 2003-11-14 2003-11-14 Pharmaceutical formulations
GB0326759A GB0326759D0 (en) 2003-11-17 2003-11-17 Pharmaceutical formulations and their preparation and use
PCT/IB2004/003886 WO2005046637A2 (en) 2003-11-14 2004-11-11 Pharmaceutical formulations employing short-chain sphingolipids and their use

Publications (1)

Publication Number Publication Date
ATE434431T1 true ATE434431T1 (de) 2009-07-15

Family

ID=34593738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798989T ATE434431T1 (de) 2003-11-14 2004-11-11 Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung

Country Status (6)

Country Link
US (2) US7915227B2 (de)
EP (1) EP1686959B1 (de)
AT (1) ATE434431T1 (de)
DE (1) DE602004021713D1 (de)
ES (1) ES2329374T3 (de)
WO (1) WO2005046637A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434431T1 (de) * 2003-11-14 2009-07-15 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
EP1817004A2 (de) * 2004-11-15 2007-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Kombinationstherapie, vorzugsweise aus einem ceramid mit einem zytotoxischen mittel
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
PL1853303T3 (pl) * 2005-02-14 2016-05-31 Dpm Therapeutics Corp Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CN101244038B (zh) * 2007-10-26 2010-12-08 吴念 稳定型阿霉素类脂质体及其制备方法
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
WO2016049250A1 (en) * 2014-09-24 2016-03-31 The Board Of Trustees Of The University Of Illinois Artificial platelets for treating catastrophic bleeding
WO2018146506A1 (en) * 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416872A (en) 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
GB8620361D0 (en) 1986-08-21 1986-10-01 Windleshaw Enterprises Ltd Pharmaceutical compositions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JP3499604B2 (ja) 1994-07-25 2004-02-23 財団法人神奈川科学技術アカデミー スフィンゴ糖脂質ミセルからなる薬物担体
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
AU2230497A (en) * 1996-02-26 1997-09-10 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
EP1053243B1 (de) * 1998-02-12 2011-03-30 Emory University Sphingolipid-derivate und verfahren zu deren verwendung
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
ATE434431T1 (de) * 2003-11-14 2009-07-15 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung

Also Published As

Publication number Publication date
WO2005046637A2 (en) 2005-05-26
US20070082855A1 (en) 2007-04-12
ES2329374T3 (es) 2009-11-25
US7915227B2 (en) 2011-03-29
WO2005046637A3 (en) 2005-07-07
US20110150984A1 (en) 2011-06-23
EP1686959A2 (de) 2006-08-09
DE602004021713D1 (de) 2009-08-06
EP1686959B1 (de) 2009-06-24

Similar Documents

Publication Publication Date Title
ATE434431T1 (de) Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
DK1521573T3 (da) Ikke-polymere, lipofile, farmaceutiske implantatsammensætninger til intrakulær anvendelse
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη
DK1543063T3 (da) Medikament levering
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
NO20064808L (no) Orale matrixformuleringer med licarbazepin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties